Physician profile
Kyla Freeman
NPI 1225522758
$1,625.90
in general payments reported to CMS, 2019-2025
15 companies · $638 in 2025
The $638 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.13 · 2020: $139 · 2022: $125 · 2023: $142 · 2024: $490 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $295.06 | 2024-2025 | Slynd |
| Astellas Pharma US INC | $240.90 | 2024-2025 | Veozah |
| Sage Therapeutics, LLC | $222.79 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $157.82 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $138.99 | 2020 | |
| Myovant Sciences INC. | $124.99 | 2022 | |
| Abbvie INC. | $93.61 | 2023-2025 | |
| Boston Scientific Corporation | $92.13 | 2019 | |
| Coopersurgical, INC. | $53.90 | 2023-2024 | Paragard T 380a, Endosee |
| Organon LLC | $53.51 | 2024-2025 | Nexplanon |
| Daiichi Sankyo INC. | $41.21 | 2024-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $35.05 | 2023 | Myfembree |
| Millicent US INC | $34.73 | 2025 | Femlyv, Intrarosa |
| Supernus Pharmaceuticals, INC. | $24.16 | 2025 | Qelbree |
| Sanara Medtech INC. | $17.05 | 2023 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.